Wolwo Pharma(300357) 全景网·2025-04-21 05:31Core Insights - The company reported a revenue of 925 million yuan for 2024, a year-on-year increase of 9.10%, and a net profit of 318 million yuan, up 2.46% from the previous year [1] - The sales revenue of the "Dust Mite Drops" reached 886 million yuan, growing by 7.86%, while the "Artemisia Pollen Sublingual Drops" saw a significant increase of 76.43% to 27 million yuan [1] - The company is a leading player in the allergy treatment market in China, focusing on the development and sales of allergy diagnosis and treatment products [2] Financial Performance - In Q1 2025, the company achieved a revenue of 228 million yuan, a 5.65% increase year-on-year, with a net profit of 74 million yuan, slightly down by 3.71% [1] - The sales of "Dust Mite Drops" in Q1 2025 were 216 million yuan, up 4.10%, while "Artemisia Pollen Sublingual Drops" increased by 43.52% to 9 million yuan [1] Market Position and Growth Potential - The company is positioned in a high-growth market for allergy treatments, with a potential market size driven by a significant number of allergy sufferers in China, estimated at 420 million people [2][3] - The company is recognized as the absolute leader in domestic desensitization treatment, with a competitive landscape that supports strong growth [3] Research and Development - The company invested 125 million yuan in R&D in 2024, accounting for 13.48% of its revenue, to enhance its product pipeline in allergy treatment [3] - The company holds 12 valid Chinese invention patents and has plans to enter new medical fields, including stem cell therapies and natural medicines [3] Product Development - The company has received approval for several new allergy testing products, expanding its portfolio to a total of 8 approved skin prick test products [4] - The company aims to improve the quality of life and health span of individuals through its innovative allergy treatment solutions [4] Shareholder Returns - The company has a consistent profit distribution policy, with a planned cash dividend of 115 million yuan for 2024, representing 36.24% of its net profit [5] - Since its listing, the company has distributed over 850 million yuan in cash dividends, significantly exceeding its initial fundraising amount [4]